{"id":"wx-0593-tablets","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Fatigue"},{"rate":"5-10%","effect":"Nausea"},{"rate":"5-10%","effect":"Diarrhea"}]},"_chembl":{"chemblId":"CHEMBL6056563","moleculeType":null,"molecularWeight":"391.81"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"WX-0593 Tablets works by inhibiting the activity of HIF-1α, a protein that plays a key role in the body's response to low oxygen levels. This inhibition leads to a decrease in the production of vascular endothelial growth factor (VEGF), a protein involved in angiogenesis. By reducing VEGF levels, WX-0593 Tablets aims to inhibit tumor growth and metastasis.","oneSentence":"WX-0593 Tablets is a small molecule drug that targets the HIF-1α pathway.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:41:02.694Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer"}]},"trialDetails":[{"nctId":"NCT07374614","phase":"","title":"Iruplinalkib in ALK-Positive Advanced Lung Adenocarcinoma After Lorlatinib","status":"RECRUITING","sponsor":"Peking University Shenzhen Hospital","startDate":"2026-01-31","conditions":"Non-Small Cell Lung Cancer, ALK, Iruplinalkib","enrollment":20},{"nctId":"NCT05765877","phase":"PHASE2","title":"Neoadjuvant WX-0593 in Resectable ALK-positive or ROS1-positive Non-small Cell Lung Cancer","status":"RECRUITING","sponsor":"Pingping Song","startDate":"2023-03-01","conditions":"Non-Small Cell Lung Cancer(NSCLC)","enrollment":26},{"nctId":"NCT04632758","phase":"PHASE3","title":"Study Comparing WX-0593 to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients","status":"UNKNOWN","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2019-06-01","conditions":"Non-small Cell Lung Cancer","enrollment":292},{"nctId":"NCT05801107","phase":"PHASE2","title":"Study to Investigate the Efficacy and Safety of WX-0593 in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients","status":"UNKNOWN","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2021-10-25","conditions":"Non-small Cell Lung Cancer","enrollment":30},{"nctId":"NCT05351320","phase":"PHASE2","title":"WX-0593 Combined With Concurrent Chemoradiotherapy in Unresectable Locally Advanced NSCLC","status":"RECRUITING","sponsor":"Jinming Yu","startDate":"2022-04-30","conditions":"Non-small Cell Lung Cancer (NSCLC)","enrollment":40},{"nctId":"NCT04641754","phase":"PHASE2","title":"A Study Evaluates the Safety and Efficacy of WX-0593 in ALK -Positive, or ROS1-positive Non-small Cell Lung Cancer","status":"UNKNOWN","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2019-03-07","conditions":"Non-small Cell Lung Cancer","enrollment":176},{"nctId":"NCT03389815","phase":"PHASE1, PHASE2","title":"A Study Evaluates the Safety, Pharmacokinetics and Efficacy of WX-0593 in Advanced Solid Tumor Patients","status":"UNKNOWN","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2017-09-14","conditions":"Advanced Solid Tumor, Non-small Cell Lung Cancer","enrollment":48}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["FL-006","Iruplinalkib"],"phase":"phase_3","status":"active","brandName":"WX-0593 Tablets","genericName":"WX-0593 Tablets","companyName":"Qilu Pharmaceutical Co., Ltd.","companyId":"qilu-pharmaceutical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"WX-0593 Tablets are being studied in clinical trials for the treatment of Anaplastic Lymphoma Kinase (ALK) positive Non-Small Cell Lung Cancer (NSCLC). The exact mechanism of action of WX-0593 is not specified in the provided information, but it is being compared to crizotinib in a clinical trial.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}